Asociación entre anticoagulante lúpico positivo y niveles  elevados de factor VIII como riesgo adicional de trombosis

Martha Castillo; Yurany  Duarte; Gloria  Ramos; María Elena  Muñoz

doi:10.22490/24629448.10150

Vol. 23 No. 45 (2025): 2.

Published 2025-07-01

license

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Research Article (before OJS)

Association between positive lupus anticoagulant and elevated levels of factor VIII as an additional risk of thrombosis

DOI: https://doi.org/10.22490/24629448.10150

Martha Castillo Universidad Colegio Mayor de Cundinamarca

Yurany Duarte Universidad Colegio Mayor de Cundinamarca

Gloria Ramos Universidad Militar Nueva Granada

María Elena Muñoz Universidad Nacional de San Marcos

PDF (Spanish)

Abstract
References

Introduction. Lupus anticoagulant (LA), an autoantibody associated with thrombotic di sorders, interferes with coagulation tests. Elevated levels of factor VIII:C have been shown to constitute an independent thrombotic risk factor.

Objective. To associate factor VIII activity in patients with positive lupus anticoagulant with an additional risk of thrombosis.

Methodology. A descriptive cross-sectional study. 51 plasma samples with positive lupus anticoagulant were evaluated, with factor VIII:C and fibrinogen assays. Nonparametric statistical tests and the parallelism test were applied to confirm true deficiencies.

Results. 42 samples had normal factor VIII:C concentrations, 5 showed mild deficiency of this fac tor, and 4 showed elevated factor VIII:C levels. Of these, 2 also had elevated fibrinogen, and one had only elevated fibrinogen. The association between lupus anticoagulant and simultaneous elevation of Factor VIII:C and fibrinogen suggests significant thrombotic risk.

Conclusions. The results demonstrate the importance of a comprehensive clinical evaluation of patients receiving lupus anticoagulant therapy, considering factor VIII:C as a marker of thrombotic risk. The parallelism test is recommended to assess factor elevations and actual risk.

keywords: Antiphospholipid syndrome, lupus anticoagulant, thrombosis, factor VIII, factor I

1. Macías Abraham, C. (2006). Moléculas de adhesión: Importancia en la respuesta inmune e inflamatoria. Revista Cubana de Hematología, Inmunología Y Hemoterapia, 22(2). http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892006000200003

2. Gómez-Gómez, B., Leopoldo Rodríguez-Weber, F., Díaz-Greene, E., Leopoldo, F., & Weber, R. (2018). Correspondencia. Med Int Méx, 34(2), 244–263. https://doi.org/10.24245/mim.v34i2.1908

3. Sarvananthan T, Das S. Thrombosis: simplified. Phlebology [Internet]. 2012 Apr [cited 2023 Aug 15];27 Suppl 2(SUPPL.2):12–22. Available from: https://pubmed.ncbi.nlm.nih.gov/22457301/

4. Mazurkiewicz-Pisarek, A., Płucienniczak, G., Ciach, T., & Płucienniczak, A. (2016). The factor VIII protein and its function. Acta Biochimica Polonica, 63(1). https://doi.org/10.18388/abp.2015_1056

5. Federici AB. The factor VIII/von Willebrand factor complex: basic and clinical issues. Haematologica [Internet]. 2003 [cited 13 Jun 2023];88(6). Available from: https://pubmed.ncbi.nlm.nih.gov/12826528/

6. Holestelle MJ, Geertzen HGM, Straatsburg IH, van Gulik TM, van Mourik JA. Factor VIII expression in liver disease. Thromb Haemost. 2004;91(2):267–75.

7. Yadav N, Kanjirakkuzhiyil S, Ramakrishnan M, Das TK, Mukhopadhyay A. Factor VIII can be synthesized in hemophilia a mice liver by bone marrow progenitor cell-derived hepatocytes and sinusoidal endothelial cells. Stem Cells Dev. 2012 Jan 1;21(1):110–20.

8. Hollestelle MJ, Poyck PPC, Hollestelle JM, Marsman HA, Van Mourik JA, Van Gulik TM. Extra-hepatic factor VIII expression in porcine fulminant hepatic failure. Journal of Thrombosis and Haemostasis [Internet]. 2005 Oct 1 [cited 2023 Jun 20];3(10):2274–80. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/j.1538-7836.2005.01543.x

9. Ling G, Tuddenham EGD. Factor VIII: the protein, cloning its gene, synthetic factor and now – 35 years later – gene therapy; what happened in between? Br J Haematol [Internet]. 2020 May 1 [cited 2023 Jul 28];189(3):400–7. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.16311

10. Kamphuisen, P. W., Eikenboom, J. C., Vos, H. L., Pablo, R., Sturk, A., Bertina, R. M., & Rosendaal, F. R. (1999). Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thrombosis and Haemostasis, 81(5), 680–683. https://pubmed.ncbi.nlm.nih.gov/10365736/

11. Lelas, A., Greinix, H. T., Wolff, D., Eissner, G., Pavletic, S. Z., & Pulanic, D. (2021). Von Willebrand Factor, Factor VIII, and Other Acute Phase Reactants as Biomarkers of Inflammation and Endothelial Dysfunction in Chronic Graft-Versus-Host Disease. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.676756

12. Inflammatory response in the acute phase of deep vein thrombosis. (2002). Journal of Vascular Surgery, 35(4), 701–706. https://doi.org/10.1067/mva.2002.121746

13. O’Donnell J, Laffan MA. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor. Transfus Med [Internet]. 2001 [cited 2023 Jul 28];11(4):343–51. Available from: https://pubmed.ncbi.nlm.nih.gov/11532189/

14. Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. Journal of Thrombosis and Thrombolysis 2016 41:1 [Internet]. 2016 Jan 16 [cited 2023 Jun 20];41(1):3–14. Available from: https://link.springer.com/article/10.1007/s11239-015-1311-6

15. Núñez-Álvarez, C. A., & Cabiedes, J. (2011). Mecanismos patogénicos de los anticuerpos antifosfolípidos. Reumatología Clínica, 7(1), 72–76. https://doi.org/10.1016/j.reuma.2009.10.005

16. Garcia, D., & Erkan, D. (2018). Diagnosis and Management of the antiphospholipid syndrome. New England Journal of Medicine, 378(21), 2010–2021. https://doi.org/10.1056/nejmra1705454

17. Semanal BE. Semana epidemiológica 23 4 al 10 de junio de 2023.

18. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost [Internet]. 1999 [cited 18 Jun 2023];81(5). Disponible en: https://pubmed.ncbi.nlm.nih.gov/10365736/

19. Cristina L, Benilde C, Michela C, Mirella F, Giuliana G, Gualtiero P. High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol [Internet]. 2004 Feb [cited 2022 Sep 11];124(4):504–10. Available from: https://pubmed.ncbi.nlm.nih.gov/14984502/

20. Kreuz W, Stoll M, Junker R, Heinecke A, Schobess R, Kurnik K, et al. Familial elevated factor VIII in children with symptomatic venous thrombosis and post-thrombotic syndrome: results of a multicenter study. Arterioscler Thromb Vasc Biol [Internet]. 2006 Aug [cited 2022 Sep 11];26(8):1901–6. Available from: https://pubmed.ncbi.nlm.nih.gov/16709943/

21. P. Vince Jenkins, Orla Rawley, Owen P. Smith and James S. O’Donnell. Haemostasis Research Group, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St James’s Hospital, Trinity College Dublin; Department of Haematology, Our Lady’s Children’s Hospital, Dublin; National Centre for Hereditary, Coagulation Disorders, St James’s Hospital, Dublin, Ireland.

22. O’Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H Antigen Expressed on Circulating von Willebrand Factor Is Modified by ABO Blood Group Genotype and Is a Major Determinant of Plasma von Willebrand Factor Antigen Levels. Arterioscler Thromb Vasc Biol [Internet]. 2002 Feb 1 [cited 2022 Sep 11];22(2):335–41. Available from: https://www.ahajournals.org/doi/abs/10.1161/hq0202.103997

23. Voicu S, Delrue M, Chousterman BG, Stépanian A, Bonnin P, Malissin I, et al. Imbalance between procoagulant factors and natural coagulation inhibitors contributes to hypercoagulability in the critically ill COVID-19 patient: clinical implications. Eur Rev Med Pharmacol Sci [Internet]. 2020 [cited 2023 Jul 28];24(17):9161–8. Available from: https://pubmed.ncbi.nlm.nih.gov/32965009/

24. Baiges A, Reverter JC, García Pagán JC. Reply to: “Factor VIII as a potential predictor of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis”. J Hepatol. 2023 Mar;78(3):e111-e112. doi:10.1016/j.jhep.2022.11.026. Epub 2022 Dec 9. PMID: 36509182.

25. Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol. 2001 May;21(5):731-8. doi: 10.1161/01.atv.21.5.731. PMID: 11348867.

26. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost. 1999 May;81(5):680-3. PMID: 10365736.

27. Castillo, M., Oliveros, A. L., Ramos, G., Muñoz Zambrano, M. E., & Mora Quimbayo, J. A. (2023). Importance of the dilution test in the dosage of coagulation factors XII and XI in plasma with positive lupus anticoagulant. REVISTA NOVA, 21(41). https://doi.org/10.22490/24629448.7539

license

How to Cite

Castillo, M., Duarte, Y., Ramos, G. ., & Muñoz, M. E. (2025). Association between positive lupus anticoagulant and elevated levels of factor VIII as an additional risk of thrombosis. NOVA Biomedical Sciences Journal, 23(45), 101-113. https://doi.org/10.22490/24629448.10150

Download Citation

Almétricas

Metrics

Metrics Loading ...

Declaración de privacidad.

Association between positive lupus anticoagulant and elevated levels of factor VIII as an additional risk of thrombosis

How to Cite